Cancer Progress

Since 1985, Cancer Progress is the only oncology conference that invites a discussion of scientific progress within the context of development, regulatory, clinical, commercial and investment perspectives in two days of interactive dialogue. Pivotal topics, frank discussions, vigorous debate, lively audience participation and generous networking throughout the meeting during breaks, luncheons, reception and dinner combine to make this a highly impactful conference.

Our 27th Annual Meeting on March 8-9, 2016 will provide an unsurpassed learning experience for participants in quality of information, coverage of issues, and value of professional contacts. The quality of the speaking faculty is a major contributor to the popularity and value of this conference.

We look forward to seeing you at the 27th Annual Cancer Progress Conference on March 8-9 at the Grand Hyatt New York in New York City!


Cancer Progress 2016 Registration Rate

Early Bird Industry (Pharma, Biotech, Device, Dx, Data) through November 30, 2015: $1900
Industry (Pharma, Biotech, Device, Dx) December 1, 2015 and beyond: $2150
Additional registrant from the same company: $1900
One Day Rate for Industry: $1350
Service Provider: $2500
One Day Rate for Service Provider: $1500

The registration fee covers your attendance at the meeting, handbook, continental breakfasts,
luncheons and reception.

Registration Cancellation Policy:

Registrants may cancel up to February 1 for a full refund less a $200 processing charge.

Cancellations after 30 days prior to the conference: Please send someone in your stead, or we will apply a
credit to Cancer Progress 2017 on your behalf.

Please submit conference refund requests to Ginny Llobell at
or call 973.292.5001 Extensions 252 or 235 for assistance.


109 East 42nd Street at Grand Central Terminal
New York, New York, USA, 10017
Tel: +1 212 883 1234

Cancer Progress has negotiated special rates for conference accommodation at the Grand Hyatt New York.

Reservations can be made by calling 1-888-421-1442 or online by clicking the button below.


Advisory Board

Steven Averbuch

Steven D. Averbuch, MD

Vice President,Translational Clinical Development & Pharmacodiagnostics, Bristol-Myers Squibb

Jeffrey M. Bockman, PhD

Vice President, Defined Health

Robert Cohen, MD

Fellow, Calico Life Sciences

Richard B. Gaynor, MD

Sr. Vice President Global Development / Medical Affairs, Oncology Business Unit, Eli Lilly and Company

Jeremy Goldberg

President, JPG Healthcare LLC

Steve Heller

Principal, OncStrat LLC

Brian Leyland-Jones, MD, PhD

Vice President of Molecular and Experimental Medicine, Avera Cancer Institute, Consulting Professor, Stanford University School of Medicine

Neal Rosen, MD, PhD

Director, Center for Mechanism-Based Therapeutics, Memorial Sloan Kettering Cancer Center


“I truly enjoyed the conference. I told several colleagues and friends that this has been one of the best conferences I have ever attended.”

Christoph Lengauer, Chief Scientific Officer

Blueprint Medicines

“What an unbelievable 2-day event that was. The intimate atmosphere (I made great new contacts) and dynamic (sometimes “dynamic tension”) interaction between panel members was fantastic. I kept great notes and have already shared the very enthusiastic feedback & takeaways with my management team.”

Armand Girard, Vice President, Corporate Development


“Thank you for the opportunity. I felt privileged to be part of a panel composed of stellar leaders within the Oncology space.”

Noemi Rosa

Novartis Inc.

“I really enjoyed the meeting as usual – great topics and speakers. I look forward to next year’s meeting!”

Richard Brian Gaynor, Sr. Vice President Global Development / Medical Affairs, Oncology Business Unit

Eli Lilly and Company